Coordinating Multi-Nation Clinical Trials in the EU: A Regulatory Perspective

The European Union (EU) presents a unique opportunity for conducting high-quality, multi-country clinical trials owing to its diverse population, robust healthcare systems, and evolving regulatory frameworks. Historically, sponsors faced challenges due to inconsistent national regulations and ethics procedures, especially when initiating trials across multiple Member States. However, the implementation of the EU Clinical Trial Regulation (CTR) 536/2014 and the launch of the Clinical Trials Information System (CTIS) aim to harmonize and streamline these processes.

In this article, we explore the requirements, operational processes, challenges, and best practices for conducting multi-country clinical trials in the EU. Whether you’re a sponsor, CRO, or investigator, understanding the harmonized regulatory framework is essential for timely and compliant trial execution.

Background and Regulatory Framework

The Challenge Before CTR 536/2014

Prior to the CTR, the EU operated under Directive 2001/20/EC. Although it was intended to harmonize trial regulations, it allowed Member States to implement the directive independently. This led to:

• Variable timelines and submission requirements
• Duplicated ethics and regulatory reviews across Member States
• Delays in trial start-up, particularly for pan-EU studies

These inconsistencies discouraged sponsors from conducting large-scale trials in Europe and slowed drug development timelines.

CTR 536/2014 and the Introduction of CTIS

The CTR, which became fully applicable on January 31, 2022, replaced the Directive and introduced a single submission portal – CTIS – for all clinical trial applications. It harmonizes and centralizes the application, assessment, and decision-making process across EU countries, supporting both single- and multi-country trials.

Core Clinical Trial Insights for Multi-Country EU Studies

1. Single Dossier Submission Through CTIS

Under the CTR, sponsors submit a single dossier via CTIS, which includes:

• Part I: Common scientific documents assessed jointly by all concerned Member States (e.g., protocol, IMPD, IB)
• Part II: Country-specific documents (e.g., informed consent forms, recruitment materials)

This eliminates the need for parallel submissions in each country, creating a unified submission workflow.

2. Coordinated Assessment Process

In a multi-country trial, one Member State acts as the “Reporting Member State (RMS)” responsible for leading the Part I assessment. The other “Concerned Member States (CMS)” review and contribute to this assessment. After finalization, each Member State completes their Part II assessment independently.

Standard timelines include:

• Part I: 45 days (extendable for specific reasons)
• Part II: 45 days from validation, running in parallel with Part I
• Decision: Each country provides its decision after both assessments are complete

3. Harmonized Yet Flexible Ethics Review

Ethics Committees (ECs) are still governed by national regulations. However, they are expected to conduct their reviews within the CTR timeline for Part II. Member States such as Belgium and the Netherlands have aligned ethics processes to fit the CTR framework, while others are still adapting.

4. Language and Localization Challenges

Even under a centralized submission system, documents like informed consent forms must be adapted and translated into local languages. This creates logistical challenges and requires advance planning by the sponsor for each participating country.

5. Role of the Sponsor in Multi-State Coordination

Sponsors must ensure:

• Consistent documentation across Part I and II
• Clear communication with NCAs and ECs in each country
• Active monitoring of questions and deadlines in CTIS
• Transparency in resolving any issues flagged by individual Member States

6. Amending a Multi-Country Trial

Substantial modifications require re-submission of impacted sections through CTIS. Changes affecting only Part II documents may only require submission to affected Member States. However, if the protocol or IMPD is altered, the RMS must reassess the Part I section and initiate a coordinated review again.

7. Trial Timelines and Delays

Although CTR introduces predictable timelines, operational bottlenecks can occur due to:

• Internal review delays at ECs
• Incomplete or inconsistent document packages
• Differences in interpretation of regulatory requirements

Therefore, pre-submission consultations are recommended to align expectations and avoid rejections.

Best Practices for Multi-Country EU Trials

• Engage early with potential RMS to discuss timeline expectations
• Use standardized document templates with country-specific adaptations
• Plan translations and localizations in advance
• Leverage local CROs or affiliates for country-specific regulatory insights
• Train team members on CTIS workflows and timelines

Scientific and Regulatory Evidence

• Regulation (EU) No 536/2014 (Clinical Trials Regulation)
• EMA CTIS Reference Guides and Module Trainings
• ICH E6(R2) – Good Clinical Practice
• National Competent Authority guidelines (e.g., BfArM, ANSM, FAMHP)
• EU Commission Q&A documents on CTR implementation

Special Considerations

Multi-country trials involving pediatric populations, rare diseases, or advanced therapies (e.g., ATMPs) require careful coordination of additional regulatory layers. Sponsors must also be mindful of:

• Data privacy requirements under GDPR
• Local pharmacovigilance obligations during development
• Informed consent models accepted in each country

When Sponsors Should Seek Regulatory Advice

• Before selecting RMS – to ensure optimal review leadership
• When planning protocol complexity involving multiple regions
• Before submitting substantial amendments across jurisdictions
• When facing divergent questions from ECs or NCAs
• For clarification on CTIS technical submissions and user roles

FAQs

1. Can I select any country as the Reporting Member State (RMS)?

Yes, but the selected country must agree to serve as RMS. Many sponsors choose the country with the fastest ethics/NCA coordination and strong regulatory experience.

2. Do all countries need to approve a multi-country CTA?

No, Member States can issue different decisions. Approval in one country does not guarantee approval in another.

3. Is CTIS mandatory for all trials?

Yes, as of January 31, 2023, all new trial applications in the EU must be submitted via CTIS.

4. Can I run a mono-country trial under CTR?

Yes. CTR applies to both single-country and multi-country trials. However, the harmonized process is particularly beneficial for multi-country trials.

5. Do I need separate insurance policies for each Member State?

Yes, insurance must comply with each country’s requirements. Coverage amounts and conditions may differ.

6. What happens if timelines are missed in CTIS?

If deadlines are missed without a justified extension, the application may be withdrawn automatically or considered rejected.

Conclusion

Multi-country clinical trials in the EU are increasingly streamlined under CTR 536/2014 and CTIS. While harmonized regulatory timelines and coordinated reviews offer significant advantages, operational and cultural differences among Member States still require strategic planning. Sponsors must combine centralized submission strategies with localized expertise to navigate ethics, language, insurance, and pharmacovigilance variations. With the right preparation, the EU can be a highly efficient region for executing global clinical development programs.

Moving Toward Ethics Review Harmonization Across the European Union

Ethics Committees (ECs) play a central role in the protection of human subjects in clinical trials. In the European Union (EU), each Member State has traditionally operated under its own set of ethics review procedures, timelines, and submission requirements. This fragmented system has historically created inconsistencies and delays, particularly for multi-country trials. However, the implementation of the EU Clinical Trial Regulation (CTR) 536/2014 aims to foster harmonization of ethics review processes while respecting national responsibilities.

This article explores the evolution of ethics committee structures in the EU, the challenges in harmonizing ethical review, and the impact of recent regulatory changes on cross-border clinical research coordination. Sponsors, CROs, and investigators must understand how to navigate the ethics landscape under this shifting regulatory paradigm to ensure ethical compliance and faster trial initiation.

Background and Regulatory Framework

Ethics Committees Before EU CTR 536/2014

Before CTR 536/2014, the EU operated under the Clinical Trials Directive 2001/20/EC, which allowed each Member State to define its own national ethics systems. As a result:

• Submission formats and documentation requirements varied widely
• Timelines were inconsistent across countries (ranging from 15 to 90 days)
• Multi-country trials faced duplicated reviews and conflicting opinions

This lack of harmonization increased administrative burden and delayed trial start-up in Europe, making the EU less competitive in global research.

EU CTR 536/2014: Shifting Toward Harmonization

The CTR, fully applicable since January 31, 2022, replaces the old Directive with a regulation that is directly applicable in all Member States. It introduces a streamlined clinical trial application (CTA) process through the Clinical Trials Information System (CTIS). While it harmonizes many regulatory elements, the ethical review remains a national responsibility. However, Member States are encouraged to align ethical assessment procedures with the Regulation’s timelines and structure.

Key Clinical Trial Ethics Harmonization Insights

1. Role of Ethics Committees in the CTA Process Under CTR

Under the CTR, a sponsor submits a single CTA dossier via CTIS. The application is divided into:

• Part I: Joint scientific assessment (protocol, IMPD, investigator brochure)
• Part II: Country-specific documents (e.g., ICF, recruitment materials)

Ethics Committees primarily contribute to the Part II assessment. Each Member State has designated national procedures for involving ECs, but must complete their review within harmonized timelines (initially 45 days with possible extension).

2. Timeline Harmonization Efforts Across Member States

While CTR sets standard deadlines, not all Member States have aligned internal ethics processes. Some countries (e.g., Netherlands, Belgium, Germany) have reformed their EC systems to comply with CTR timelines. Others continue to face operational challenges, especially where multiple regional ECs must coordinate reviews.

For instance, Germany has consolidated its numerous ECs under BfArM oversight for CTR-aligned processes. Belgium has centralized EC functions under the FAMHP in collaboration with select ethics committees for CTR submissions.

3. Submission Formats and Digital Tools

CTIS serves as the unified submission and communication platform across the EU. However, some ECs still require parallel submissions or additional forms for local legal or language requirements. Harmonization is ongoing in:

• Digital signatures acceptance
• Use of national ethics portals vs. CTIS-only systems
• Translation requirements for ICFs and patient-facing documents

4. National Legal and Cultural Variations

Despite CTR’s unifying intent, EC operations remain influenced by local laws and ethics norms. Differences exist in:

• Composition of ECs (e.g., inclusion of lay members, legal experts)
• Use of central vs. regional ECs
• Consent for vulnerable populations (e.g., pediatrics, elderly)

This necessitates tailored Part II submissions for each country, despite using a centralized portal.

Best Practices for Ethics Committee Engagement in EU Trials

• Early dialogue with National Competent Authorities (NCAs) and local ECs to understand submission expectations
• Prepare multilingual ICFs that meet local readability standards
• Develop a country-specific Part II document strategy aligned with ethics norms
• Monitor national implementations of CTR and ethical review SOPs
• Use CTIS consistently for official communications and document exchange

Scientific and Regulatory Evidence

• EU Clinical Trial Regulation (CTR) 536/2014
• European Medicines Agency (EMA) guidance on ethics review under CTR
• CTIS training modules and user manuals
• Directive 2001/20/EC (repealed)
• GCP guidelines (ICH E6 R2)

Special Considerations in Ethics Harmonization

Trial sponsors conducting multi-country trials must assess variations in:

• Language requirements for patient materials
• Legal capacity and surrogate consent regulations
• Regional sensitivities regarding trial populations (e.g., minors, terminally ill)

Centralized ethics systems (like in the UK under MHRA) offer lessons in harmonization that the EU may adopt more broadly. The growing use of eConsent and digital health also requires ethics alignment across borders.

When Sponsors Should Strategically Engage with Ethics Committees

• During study feasibility: clarify EC procedures in each country
• At protocol finalization: confirm ICF templates meet national expectations
• Pre-CTA submission: schedule ethics timelines to avoid delays
• Post-submission: track questions from ECs and respond within deadlines
• Post-approval: ensure consistent ethics oversight and annual safety updates

FAQs

1. Are ethics committee reviews fully harmonized across the EU?

No, ethics reviews are still governed by national processes. CTR introduces timeline consistency, but Member States retain operational autonomy.

2. What happens if an ethics committee rejects Part II of a CTA?

If Part II is rejected, the CTA is rejected for that Member State. Sponsors can revise and resubmit, but the application won’t proceed until all conditions are met.

3. Do all countries use central ethics committees?

No. Some countries like Denmark or Belgium have centralized systems, while others like Spain or Italy may involve regional or institutional ECs.

4. How do sponsors ensure ethical consistency in multi-country trials?

By developing core templates and adapting them locally, maintaining strong documentation, and working with regional affiliates to align ethics responses.

5. Is ethics approval required before submitting through CTIS?

No. Under CTR, ethics reviews happen as part of the integrated assessment process. However, local site initiation may still depend on final EC approval.

6. Are all ethics opinions publicly available?

CTR enhances transparency, but not all Member States publish full ethics opinions. Summaries may be uploaded to CTIS post-decision.

Conclusion

Harmonizing ethics committee procedures remains one of the most complex yet critical goals in streamlining EU clinical trials. While the CTR lays the groundwork for consistency in timelines and structure, full harmonization depends on national implementations, digital readiness, and inter-agency coordination. Sponsors must proactively engage with ethics frameworks in each Member State, anticipate procedural differences, and leverage CTIS to enable timely, compliant trial approvals across the EU.